Increased expression of RIPOR1 predicts the poor prognosis of colorectal cancer patients.

IF 1.5 4区医学 Q4 ONCOLOGY

Translational cancer research Pub Date : 2025-05-30 Epub Date: 2025-05-12 DOI:10.21037/tcr-24-2029

Xiaolei Yue, Junyu Bian, Zhikun Dong, Yonglin Chen

{"title":"Increased expression of RIPOR1 predicts the poor prognosis of colorectal cancer patients.","authors":"Xiaolei Yue, Junyu Bian, Zhikun Dong, Yonglin Chen","doi":"10.21037/tcr-24-2029","DOIUrl":null,"url":null,"abstract":"Background: Colorectal cancer (CRC) is considered one of the main causes of cancer-related deaths. Rho family-interacting cell polarization regulator 1 (RIPOR1) is a new Rho effector protein, and its abnormal expression may be related to various tumors. However, its expression and significance in CRC are still unclear. We aimed to explore its role and potential value in CRC, and to provide a new theoretical basis of prognostic evaluation and targeted therapy for CRC patients.Methods: Here we investigated the expression and significance of RIPOR1 from public databases by using bioinformatics methods. Immunohistochemistry (IHC) was performed to determine protein expression levels of RIPOR1 in CRC patients, and the correlation between RIPOR1 expression and clinicopathological characteristics was analyzed. In vitro cellular experiments were used to explore the role of RIPOR1 in CRC cell lines.Results: Both bioinformatics analysis and IHC results demonstrated that RIPOR1 was significantly overexpressed in CRC, which was associated with a worse prognosis. The microRNA (miRNA) database showed that hsa-miR-625-5p was significantly and negatively correlated with RIPOR1. RIPOR1 may affect immune cell infiltration in CRC. Cell Counting Kit-8 (CCK-8) assay revealed that RIPOR1 promoted cell proliferation in CRC.Conclusions: RIPOR1 has a significant impact on the development and proliferation of CRC, and may be a potential predictive biomarker.","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 5","pages":"2707-2721"},"PeriodicalIF":1.5000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170205/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-2029","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colorectal cancer (CRC) is considered one of the main causes of cancer-related deaths. Rho family-interacting cell polarization regulator 1 (RIPOR1) is a new Rho effector protein, and its abnormal expression may be related to various tumors. However, its expression and significance in CRC are still unclear. We aimed to explore its role and potential value in CRC, and to provide a new theoretical basis of prognostic evaluation and targeted therapy for CRC patients.

Methods: Here we investigated the expression and significance of RIPOR1 from public databases by using bioinformatics methods. Immunohistochemistry (IHC) was performed to determine protein expression levels of RIPOR1 in CRC patients, and the correlation between RIPOR1 expression and clinicopathological characteristics was analyzed. In vitro cellular experiments were used to explore the role of RIPOR1 in CRC cell lines.

Results: Both bioinformatics analysis and IHC results demonstrated that RIPOR1 was significantly overexpressed in CRC, which was associated with a worse prognosis. The microRNA (miRNA) database showed that hsa-miR-625-5p was significantly and negatively correlated with RIPOR1. RIPOR1 may affect immune cell infiltration in CRC. Cell Counting Kit-8 (CCK-8) assay revealed that RIPOR1 promoted cell proliferation in CRC.

Conclusions: RIPOR1 has a significant impact on the development and proliferation of CRC, and may be a potential predictive biomarker.

查看原文本刊更多论文

RIPOR1表达升高预示结直肠癌患者预后不良。

背景：结直肠癌（CRC）被认为是癌症相关死亡的主要原因之一。Rho家族相互作用细胞极化调节因子1 （RIPOR1）是一种新的Rho效应蛋白，其异常表达可能与多种肿瘤有关。然而，其在结直肠癌中的表达及意义尚不清楚。我们旨在探讨其在结直肠癌中的作用和潜在价值，为结直肠癌患者的预后评估和靶向治疗提供新的理论依据。方法：采用生物信息学方法对公共数据库中RIPOR1基因的表达及其意义进行研究。采用免疫组化（IHC）方法检测结直肠癌患者中RIPOR1蛋白表达水平，并分析RIPOR1表达与临床病理特征的相关性。体外细胞实验探讨了RIPOR1在结直肠癌细胞系中的作用。结果：生物信息学分析和免疫组化结果均表明，RIPOR1在结直肠癌中显著过表达，与预后较差相关。microRNA （miRNA）数据库显示，hsa-miR-625-5p与RIPOR1呈显著负相关。RIPOR1可能影响结直肠癌免疫细胞浸润。细胞计数试剂盒-8 （CCK-8）检测显示，RIPOR1促进结直肠癌细胞增殖。结论：RIPOR1对结直肠癌的发生和增殖有重要影响，可能是一种潜在的预测性生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational cancer research ONCOLOGY-

CiteScore

2.10

自引率

0.00%

发文量

252

期刊介绍： Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.